{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-061834","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2026-09-14T20:07:12+00:00","discovered_at":"2026-09-14T20:08:24.456316+00:00","generated_at":"2026-09-14T20:08:29.901808+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Contineum's MOONLIGHT-1 Phase 2 trial fails primary endpoint in MDD","bullets":["MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 in MDD did not meet primary efficacy endpoint.","Primary endpoint: MADRS total score change at Day 5 vs placebo; no new safety signals.","JNJ-5120/PIPE-307 developed by J&J under global license; J&J evaluating exploratory endpoints.","Randomized, double-blind, placebo-controlled proof-of-concept trial in adult MDD (NCT06785012)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-061834","json":"https://secwatch.observer/filing/0001628280-26-061834.json","markdown":"https://secwatch.observer/filing/0001628280-26-061834.md","text":"https://secwatch.observer/filing/0001628280-26-061834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/0001628280-26-061834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/ctnm-20260914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:08:29.901808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}